Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention

References

• Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation82(Suppl. 3), II47–II59 (1990).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation116, e148–e304 (2007).
   PubMed Web of Science ®Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al.; ACC/AHA/SCAI. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol.51, 172–209 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJG et al.; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358, 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N. Engl. J. Med.352, 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al.; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366, 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294, 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J. Am. Coll. Cardiol.49, 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. ADP receptor antagonism: what’s in the pipeline? Am. J. Cardiovasc. Drugs7, 423–432 (2007).
   PubMed Web of Science ®Google Scholar
• Farid NA, McIntosh M, Garofolo F et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom.21, 169–179 (2007).
   PubMed Web of Science ®Google Scholar
• Williams ET, Jones KO, Ponsler GD et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos.36, 1227–1232 (2008).
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol. Ther.81, 735–741 (2007).
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos.35, 1096–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response. Am. J. Cardiol.98(Suppl. 1), 200M (2006) (Abstract).
   Web of Science ®Google Scholar
• Sugidachi A, Ogawa T, Kurihara A et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J. Thromb. Haemost.5, 1545–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J.153, 66.e9–66.e16 (2007).
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J.27, 1166–1173 (2006).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation116, 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J.29, 21–30 (2008).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357, 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation111, 3366–3373 (2005).
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J. Am. Coll. Cardiol.51, 2028–2033 (2008).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med.339, 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation98, 2126–2132 (1998).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation98, 1597–1603 (1998).
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334, 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation102, 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation101, 2823–2828 (2000).
   PubMed Web of Science ®Google Scholar
• Kawaguchi R, Angiolillo DJ, Futamatsu H, Suzuki N, Bass TA, Costa MA. Stent thrombosis in the era of drug eluting stents. Minerva Cardioangiol.55, 199–211 (2007).
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet371, 1353–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Morrow DA. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the TRITON-TIMI 38 trial. Presented at: The European Society of Cardiology Congress. Munich, Germany, 30 August–3 September 2008.
   Google Scholar
• Murphy SA, Antman EM, Wiviott SD et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur. Heart J.29, 2473–2479 (2008).
   PubMed Web of Science ®Google Scholar
• Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA298, 765–775 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Antiplatelet therapy in Type 2 diabetes mellitus. Curr. Opin. Endocrinol. Diabetes Obes.14, 124–131 (2007).
   PubMedGoogle Scholar
• Ferroni P, Basili S, Falco A, Davi G. Platelet activation in Type 2 diabetes mellitus. J. Thromb. Haemost.2, 1282–1291 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes54, 2430–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Ramirez C et al. Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol.48, 298–304 (2006).
   PubMed Web of Science ®Google Scholar
• Geisler T, Anders N, Paterok M et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care30, 372–374 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation115, 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabate M et al. Impact of platelet reactivity on cardiovascular outcomes in patients with Type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol.50, 1541–1547 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – thrombolysis in myocardial infarction 38. Circulation118, 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E et al.; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet373, 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Michelson AD, Braunwald E et al.; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 Trial. Circulation118(Suppl. 1), S814 (2008) (Abstract).
   Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360, 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J.25, 1903–1910 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Palazuelos J et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb. Haemost.99, 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, Pepe LL, Montanaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation111, 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol.48, 1339–1345 (2006).
   PubMed Web of Science ®Google Scholar